OBJECTIVES: Somatic mutations in mediator complex subunit 12 (MED12) have emerged as a critical genetic change in the development of uterine leiomyomas. Studies, however, have focused largely on cohorts consisting of Caucasian patients. In this study, uterine leiomyomas from Chinese patients were examined for MED12 mutations. In addition, polymerase chain reaction (PCR)-based high-resolution melting analysis (HRMA) was compared with direct sequencing as a potentially more sensitive method for the detection of MED12 mutations. METHODS: Tissue samples with the pathologies of uterine leiomyoma (n=181) and other endometrial diseases (n=157) were collected from Chinese patients at the Taizhou People's Hospital and Taizhou Polytechnic College (Taizhou City, China). Genomic DNA was prepared from all samples. Both PCR-based HRMA and PCR-based direct sequencing were used to detect MED12 mutations. RESULTS: PCR-based HRMA and direct sequencing revealed MED12 mutations in 95/181 (52.5%) and 93/181 (51.4%) uterine leiomyomas, respectively. Nearly half of these mutations (46/93) were found in a single codon, codon 131. The coincidence rate between the two methods was 98.9% (179/181) so that no statistically significant difference was evident in the application of the methodologies (χ(2)=0.011, p=0.916). In addition, MED12 mutations were identified in 1/157 (4.17%) case of other endometrial pathologies by both methods. CONCLUSIONS: MED12 mutations were closely associated with the development of uterine leiomyomas, as opposed to other uterine pathologies in Chinese patients, and PCR-based HRMA was found to be a reliable method for the detection of MED12 mutations.
OBJECTIVES: Somatic mutations in mediator complex subunit 12 (MED12) have emerged as a critical genetic change in the development of uterine leiomyomas. Studies, however, have focused largely on cohorts consisting of Caucasian patients. In this study, uterine leiomyomas from Chinese patients were examined for MED12 mutations. In addition, polymerase chain reaction (PCR)-based high-resolution melting analysis (HRMA) was compared with direct sequencing as a potentially more sensitive method for the detection of MED12 mutations. METHODS: Tissue samples with the pathologies of uterine leiomyoma (n=181) and other endometrial diseases (n=157) were collected from Chinese patients at the Taizhou People's Hospital and Taizhou Polytechnic College (Taizhou City, China). Genomic DNA was prepared from all samples. Both PCR-based HRMA and PCR-based direct sequencing were used to detect MED12 mutations. RESULTS: PCR-based HRMA and direct sequencing revealed MED12 mutations in 95/181 (52.5%) and 93/181 (51.4%) uterine leiomyomas, respectively. Nearly half of these mutations (46/93) were found in a single codon, codon 131. The coincidence rate between the two methods was 98.9% (179/181) so that no statistically significant difference was evident in the application of the methodologies (χ(2)=0.011, p=0.916). In addition, MED12 mutations were identified in 1/157 (4.17%) case of other endometrial pathologies by both methods. CONCLUSIONS:MED12 mutations were closely associated with the development of uterine leiomyomas, as opposed to other uterine pathologies in Chinese patients, and PCR-based HRMA was found to be a reliable method for the detection of MED12 mutations.
Authors: Mikko Turunen; Jason M Spaeth; Salla Keskitalo; Min Ju Park; Teemu Kivioja; Alison D Clark; Netta Mäkinen; Fangjian Gao; Kimmo Palin; Helka Nurkkala; Anna Vähärautio; Mervi Aavikko; Kati Kämpjärvi; Pia Vahteristo; Chongwoo A Kim; Lauri A Aaltonen; Markku Varjosalo; Jussi Taipale; Thomas G Boyer Journal: Cell Rep Date: 2014-04-18 Impact factor: 9.423
Authors: Sidong Huang; Michael Hölzel; Theo Knijnenburg; Andreas Schlicker; Paul Roepman; Ultan McDermott; Mathew Garnett; Wipawadee Grernrum; Chong Sun; Anirudh Prahallad; Floris H Groenendijk; Lorenza Mittempergher; Wouter Nijkamp; Jacques Neefjes; Ramon Salazar; Peter Ten Dijke; Hidetaka Uramoto; Fumihiro Tanaka; Roderick L Beijersbergen; Lodewyk F A Wessels; René Bernards Journal: Cell Date: 2012-11-21 Impact factor: 41.582
Authors: Shu-Yu Wu; Nancy Hernandez de Borsetti; Emily J Bain; Christopher R Bulow; Joshua T Gamse Journal: Dev Biol Date: 2013-10-30 Impact factor: 3.582
Authors: K Kämpjärvi; N Mäkinen; O Kilpivaara; J Arola; H-R Heinonen; J Böhm; O Abdel-Wahab; H J Lehtonen; L M Pelttari; M Mehine; H Schrewe; H Nevanlinna; R L Levine; P Hokland; T Böhling; J-P Mecklin; R Bützow; L A Aaltonen; P Vahteristo Journal: Br J Cancer Date: 2012-09-20 Impact factor: 7.640
Authors: Mark A Hayden; Zehra Ordulu; C Scott Gallagher; Bradley J Quade; Raymond M Anchan; Nia Robinson Middleton; Serene S Srouji; Elizabeth A Stewart; Cynthia C Morton Journal: Cancer Genet Date: 2018-02-19
Authors: Min Ju Park; Hailian Shen; Nam Hee Kim; Fangjian Gao; Courtney Failor; Jennifer F Knudtson; Jessica McLaughlin; Sunil K Halder; Tuomas A Heikkinen; Pia Vahteristo; Ayman Al-Hendy; Robert S Schenken; Thomas G Boyer Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Jennifer A Bennett; Britta Weigelt; Sarah Chiang; Pier Selenica; Ying-Bei Chen; Ann Bialik; Rui Bi; Anne M Schultheis; Raymond S Lim; Charlotte K Y Ng; Vicente Morales-Oyarvide; Robert H Young; Victor E Reuter; Robert A Soslow; Esther Oliva Journal: Mod Pathol Date: 2017-06-30 Impact factor: 7.842
Authors: Tuomas Heikkinen; Anna Äyräväinen; Janne Hänninen; Terhi Ahvenainen; Ralf Bützow; Annukka Pasanen; Pia Vahteristo Journal: Hum Reprod Open Date: 2018-11-17
Authors: Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy Journal: Endocr Rev Date: 2022-07-13 Impact factor: 25.261
Authors: Abdul K Siraj; Tariq Masoodi; Rong Bu; Poyil Pratheeshkumar; Nasser Al-Sanea; Luai H Ashari; Alaa Abduljabbar; Samar Alhomoud; Fouad Al-Dayel; Fowzan S Alkuraya; Khawla S Al-Kuraya Journal: Gut Date: 2017-02-09 Impact factor: 23.059